How I treat squamous ENT cancer
暂无分享,去创建一个
[1] Christopher U. Jones,et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial , 2019, The Lancet.
[2] M. Merlano,et al. Immunotherapy in Head and Neck Squamous Cell Cancer , 2018, Clinical and experimental otorhinolaryngology.
[3] C. Ferté,et al. High incidence of cetuximab-related infusion reactions in head and neck patients , 2018, ESMO Open.
[4] S. Kannan,et al. Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] V. Grégoire,et al. Long-term update of the 24954 EORTC phase III trial on larynx preservation. , 2016, European journal of cancer.
[6] K. Harrington,et al. Evaluation of the benefit and use of multidisciplinary teams in the treatment of head and neck cancer. , 2016, Oral oncology.
[7] K. Ang,et al. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] R. Weber,et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] M. Merlano,et al. Impact of age on acute toxicity induced by bio- or chemo-radiotherapy in patients with head and neck cancer. , 2012, Oral oncology.
[10] G. Calais,et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. , 2009, Journal of the National Cancer Institute.
[11] J. Pignon,et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[12] C. Bokemeyer,et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. , 2008, The New England journal of medicine.
[13] E. Genden,et al. Adjuvant radiotherapy and survival for patients with node-positive head and neck cancer: an analysis by primary site and nodal stage. , 2008, International journal of radiation oncology, biology, physics.
[14] R. Gilbert,et al. Postoperative chemoradiotherapy for advanced squamous cell carcinoma of the head and neck: A systematic review with meta‐analysis , 2007, Head and Neck.
[15] M. Merlano,et al. A systematic review of current and emerging approaches in the field of larynx preservation. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.